Vesicular monoamine transporter (VMAT) neurons are neurons that express VMAT proteins responsible for packaging monoamine neurotransmitters into synaptic vesicles. VMAT2, the predominant CNS isoform, is essential for dopamine, serotonin, norepinephrine, and histamine neurotransmission. These neurons are critical for synaptic vesicle function and are implicated in Parkinson's disease, addiction, and psychiatric disorders.
| Property |
Value |
| Category |
Synaptic Transmission |
| Location |
Synaptic vesicles (presynaptic terminals) |
| Transporters |
VMAT1 (peripheral), VMAT2 (central) |
| Substrates |
Dopamine, Serotonin (5-HT), Norepinephrine, Histamine |
| Key Markers |
VMAT2, TH, DAT, SERT, NET |
- Primarily expressed in peripheral tissues
- Adrenal medulla, sympathetic nerves
- Less studied in CNS
- Polymorphisms affect behavior
- Predominant CNS isoform
- Expressed in all monoaminergic neurons
- Essential for vesicular storage
- Drug target for movement disorders
- Active transport: Uses proton gradient
- V-ATPase: Creates electrochemical gradient
- Storage: Protects from degradation
- Release: Calcium-triggered exocytosis
- Dopamine: Motor control, reward
- Serotonin: Mood, sleep, appetite
- Norepinephrine: Arousal, attention
- Histamine: Wakefulness, appetite
- Nurr1: Dopaminergic neuron development
- Pitx3: VMAT2 expression
- Activity-dependent: Chronic activation
- Phosphorylation: Modulates activity
- Protein interactions: Synaptic proteins
- Trafficking: Vesicle localization
- VMAT2 imaging: 18F-FP-CIT PET
- Presynaptic marker: Diagnosis
- Vesicular dysfunction: Early event
- Alpha-synuclein effects: Impaired packaging
- Neuroprotection: VMAT2 upregulation
- Tetrabenazine: VMAT2 inhibitor
- Treats Huntington's chorea
- Reduces dopamine release
- Valbenazine: VMAT2 inhibitor
- Approved for tardive dyskinesia
- Better tolerability
- Addiction: VMAT2 and dopamine
- Depression: Altered monoamine storage
- Schizophrenia: VMAT2 polymorphisms
- Bipolar disorder: Lithium effects
- VMAT2 binding reduced in PD
- Correlates with disease severity
- Early biomarker potential
- Therapeutic target
- Oxidative stress: Damages VMAT2
- Alpha-synuclein: Interferes with function
- Mitochondrial dysfunction: Energy failure
- Protein aggregates: Impaired trafficking
- Tetrabenazine: First-generation
- Valbenazine: Improved profile
- Deutetrabenazine: Deuterated
- Small molecules: Increase activity
- Gene therapy: Viral delivery
- Protein stabilization: Chaperones
The study of Vesicular Monoamine Transporter Neurons has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.